An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Rituximab (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celltrion
- 09 Jun 2017 Results published in the BioDrugs
- 25 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2014 Planned End Date changed from 30 Sep 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.